Association between rs4149056 variant in SLCO1B1 and early discontinuation of statin after acute myocardial infarction

Pharmacogenomics. 2020 Feb;21(3):163-172. doi: 10.2217/pgs-2019-0109.

Abstract

Data from two French surveys were used to analyze the association between in-hospital statin discontinuation and SLCO1B1 polymorphism (rs4149056) in patients with acute myocardial infarction. Using TaqMan allelic discrimination assay, 1674 and 1708 patients were genotyped for SLCO1B1 in 2005 and 2010, respectively. The association with in-hospital statin discontinuation was assessed after adjusting for confounding factors. In 2005, homozygosity for the reduced-function allele was associated with an increased risk of in-hospital statin discontinuation (OR: 3.68; p = 0.004) compared with the wild-type allele but this association disappeared in 2010. However, statin type and intensity-dose differed significantly between the surveys. SLCO1B1 polymorphism (rs4149056) does not seem to be a major determinant of early 'in-hospital' statin discontinuation after acute myocardial infarction.

Keywords: SLCO1B1 polymorphism; acute myocardial infarction; drug transporters; statin therapy; statin-induced myopathy.

MeSH terms

  • Aged
  • Assessment of Medication Adherence*
  • Clinical Trials as Topic
  • Female
  • Genotype
  • Homozygote
  • Hospitalization / statistics & numerical data*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacokinetics
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Liver-Specific Organic Anion Transporter 1 / genetics*
  • Male
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / epidemiology
  • Polymorphism, Single Nucleotide*

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Liver-Specific Organic Anion Transporter 1
  • SLCO1B1 protein, human